Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis

Molecular Carcinogenesis

Volumn 46, Issue 2, 2007, Pages 130-143

  Cai, Kathy Qi ^a   Yang, Wan Lin ^a   Capo Chichi, Callinice D ^a   Vanderveer, Lisa ^a   Wu, Hong ^a   Godwin, Andrew K ^a   Xu, Xiang Xi ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Basement membrane; Epithelium; MMPs; Ovarian cancer; Preneoplastic changes

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; BASEMENT MEMBRANE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; EPITHELIUM; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; NEOPLASM; NORTHERN BLOTTING; OVARIECTOMY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS;

EID: 33847072112     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20273     Document Type: Article

References (39)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev 2001;22:255-288.
2. Bissell MJ, Barcellos-Hoff MH. The influence of extracellular matrix on gene expression: Is structure the message? J Cell Sci 1987;8:327-343.
3. Adams JC, Watt FM. Regulation of development and differentiation by the extracellular matrix. Development 1993;117:1183-1198.
4. Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, Hamilton TC, Godwin AK, Xu XX. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 2002;95:1802-1815.
5. Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 2003;98:2607-2623.
6. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-463.
7. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-564.
8. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 1998;12:569-576.
9. Yang WL, Godwin AK, Xu XX. Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: Molecular basis linking ovulation and cancer risk. Cancer Res 2004;64:1534-1540.
10. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
11. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993;82:181-186.
12. Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-1820.
13. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-390.
14. Yang DH, Smith ER, Cohen C, et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 2002;94:2380-2392.
15. Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX. Loss of Disabled-2 is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104-3113.
16. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-57.
17. Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000;19:4847-4854.
18. Mok SC, Chan WY, Wong KK, et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998;16:2381-2387.
19. Yang D-H, Smith ER, Roland IH, et al. Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Dev Biol 2002;251:27-44.
20. Capo-Chichi CD, Roland IH, Vanderveer L, et al. Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res 2003;63:4967-4977.
21. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002;346:1660-1662.
22. Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992;167:729-735.
23. Richards JS, Russell DL, Ochsner S, Espey LL. Ovulation: New dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 2002;64:69-92.
24. Liao J, Wolfman JC, Wolfman A. K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J Biol Chem 2003;278:31871-31878.
25. Han X, Boyd PJ, Colgan S, Madri JA, Haas TL. Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. J Biol Chem 2003;278:47785-47791.
26. Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG. MMP-2: Expression, activation and inhibition. Enzyme Protein 1996;49:7-19.
27. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinase and their role in tumor progression. Invasion Metastasis 1994;14:234-245.
28. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Jr., Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994;56:552-559.
29. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000;77:369-376.
30. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-2404.
31. Garzetti GG, Ciavattini A, Lucarini G, et al. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 1999;85:2219-2225.
32. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994;58:50-56.
33. Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-298.
34. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
35. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387-2392.
36. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 1998;58:5500-5506.
37. Fathalla MF. Incessant ovulation-A factor in ovarian neoplasia? Lancet 1971;2:163.
38. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721.
39. Smith ER, Xu XX. Etiology of epithelial ovarian cancer: A cellular mechanism for the role of gonadotropins. Gyn Oncol 2003;91:1-2.